Skip to main content
Contact Us
Subscribe
E-Edition
43°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Monte Rosa Therapeutics Inc
(NQ:
GLUE
)
9.110
+0.510 (+5.93%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monte Rosa Therapeutics Inc
< Previous
1
2
3
4
Next >
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
March 14, 2024
GLUE stock results show that Monte Rosa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Monte Rosa Therapeutics: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
March 11, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst
February 15, 2024
Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Monte Rosa Therapeutics: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 31, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
January 16, 2024
Analysts have high hopes for these three innovation companies in 2024.
Via
The Motley Fool
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
January 10, 2024
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
January 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 13, 2023
Via
Benzinga
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
November 21, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
November 07, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
October 27, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
October 26, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Crude Oil Moves Lower; Bank of America Profit Beats Expectations
October 17, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 17, 2023
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 17, 2023
Via
Benzinga
Dow Surges 100 Points; Goldman Sachs Posts Upbeat Earnings
October 17, 2023
U.S. stocks traded mostly higher midway through trading, with the Dow Jones falling gaining around 100 points on Tuesday. The Dow traded up 0.31% to 34,090.15 while the NASDAQ fell 0.05% to 13,560.52....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
October 17, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
October 17, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
July 26, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
May 23, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.